The effect of peroxisome proliferatoractivated receptor-c ligands on in vitro and in vivo models of COPD

European Respiratory Journal

Volumn 43, Issue 2, 2014, Pages 409-420

  Lea, Simon ^a   Plumb, Jonathan ^a   Metcalfe, Hannah ^a   Spicer, Dianne ^b   Woodman, Paul ^b   Fox, J Craig ^c   Singh, Dave ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Argenta Discovery Ltd   (United Kingdom)

^c Pulmagen Therapeutics (Inflammation) Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CCL5 PROTEIN, HUMAN; CCL5 PROTEIN, MOUSE; CORTICOSTEROID; DEXAMETHASONE; INTERLEUKIN 8; LIGAND; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RANTES; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANIMAL; APOPTOSIS; ARTICLE; BLOOD; C57BL MOUSE; CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; MOUSE; NEUTROPHIL; PATHOPHYSIOLOGY; SMOKING;

ADRENAL CORTEX HORMONES; AGED; ANIMALS; APOPTOSIS; CHEMOKINE CCL5; DEXAMETHASONE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN-8; LIGANDS; LIPOPOLYSACCHARIDES; MACROPHAGES; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEUTROPHILS; PPAR GAMMA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893461621     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00187812     Document Type: Article

References (44)

1. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor c agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533: 101-109.
2. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-D12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARc. Cell 1995; 83: 803-812.
3. Forst T, Karagiannis E, Lübben G, et al. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008; 197: 311-317.
4. Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferatoractivated receptor-c. Nature 1998; 395: 137-143.
5. Amoruso A, Bardelli C, Gunella G, et al. Quantification of PPAR-c protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine. Life Sci 2007; 81: 906-915.
6. Ghisletti S, Huang W, Ogawa S, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARc. Mol Cell 2007; 25: 57-70.
7. von Knethen A, Neb H, Morbitzer V, et al. PPARc stabilizes HO-1 mRNA in monocytes/macrophages which affects IFN-b expression. Free Radic Biol Med 2011; 51: 396-405.
8. Malur A, McCoy AJ, Arce S, et al. Deletion of PPARc in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J Immunol 2009; 182: 5816-5822.
9. Gautier EL, Chow A, Spanbroek R, et al. Systemic analysis of PPARc in mouse macrophage populations reveals marked diversity in expression with critical roles in resolution of inflammation and airway immunity. J Immunol 2012; 189: 2614-2624.
10. Birrell MA, Patel HJ, McCluskie K, et al. PPAR-c agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 2004; 24: 18-23.
11. Narala VR, Ranga R, Smith MR, et al. Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. Respir Res 2007; 8: 90.
12. Majai G, Sarang Z, Csomós K, et al. PPARc-dependent regulation of human macrophages in phagocytosis of apoptotic cells. Eur J Immunol 2007; 37: 1343-1354.
13. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003; 54: 113-129.
14. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515-548.
15. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
16. Kunz LI, Lapperre TS, Snoeck-Stroband JB, et al. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir Res 2011; 12: 34.
17. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
18. Armstrong J, Sargent C, Singh D. Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol 2009; 158: 74-83.
19. Armstrong J, Harbron C, Lea S, et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2011; 338: 732-740.
20. Southworth T, Metryka A, Lea S, et al. IFN-c synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br J Pharmacol 2012; 166: 2070-2083.
21. Richards DB, Bareille P, Lindo EL, et al. Treatment with a peroxisomal proliferator activated receptor c agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial. RespirMed 2009; 104: 668-674.
22. Spears M, Donnelly I, Jolly L, et al. Bronchodilatory effect of the PPAR-c agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther 2009; 86: 49-53.
23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
24. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2013. www.goldcopd.org/ guidelines-global-strategy-for-diagnosis-management.html Date last accessed: September 2, 2012. Date last updated: February 2013.
25. Sears DD, Hsiao A, Ofrecio JM, et al. Selective modulation of promoter recruitment and transcriptional activity of PPARc. Biochem Biophys Res Commun 2007; 364: 515-521.
26. Dasu MR, Park S, Devaraj S, et al. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009; 150: 3457-3464.
27. Chen X, Osborne MC, Rybczynski PJ, et al. Pharmacological profile of a novel, non-TZD PPARc agonist. Diabetes Obes Metab 2005; 7: 536-546.
28. Plumb J, Smyth LJ, Adams HR, et al. Increased T-regulatory cells within lymphocyte follicles in moderate COPD. Eur Respir J 2009; 34: 89-94.
29. Ishii T, Wallace AM, Zhang X, et al. Stability of housekeeping genes in alveolar macrophages from COPD patients. Eur Respir J 2006; 27: 300-306.
30. Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest 2008; 134: 606-612.
31. Bauer CM, Zavitz CC, Botelho FM, et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One 2010; 5: e13251.
32. Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf 2012; 11: 565-579.
33. Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest 2013; 143: 798-807.
34. Szanto A, Balint BL, Nagy ZS, et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARcregulated gene expression in macrophages and dendritic cells. Immunity 2010; 33: 699-712.
35. Asada K, Sasaki S, Suda T, et al. Antiinflammatory roles of peroxisome proliferator-activated receptor c in human alveolar macrophages. Am J Respir Crit Care Med 2004; 169: 195-200.
36. Shu H, Wong B, Zhou G, et al. Activation of PPARa or c reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000; 267: 345-349.
37. Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005; 122: 707-721.
38. Ricote M, Welch JS, Glass CK. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-c. Horm Res 2000; 54: 275-280.
39. Ricote M, Huang JT, Welch JS, et al. The peroxisome proliferator- activated receptorc (PPARc) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999; 66: 733-739.
40. Miotto D, Ruggieri MP, Boschetto P, et al. Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. Eur Respir J 2003; 22: 602-608.
41. Kent LM, Fox SM, Farrow SN, et al. The effects of dexamethasone on cigarette smoke induced gene expression changes in COPD macrophages. Int Immunopharmacol 2010; 10: 57-64.
42. Maestrelli P, Páska C, Saetta M, et al. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J 2003; 21: 971-976.
43. Savill J, Hogg N, Ren Y, et al. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992; 90: 1513-1522.
44. Fadok VA, Warner ML, Bratton DL, et al. CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (avb3). J Immunol 1998; 161: 6250-6257.